Marshall Wace’s ACELYRIN SLRN Stock Holding History

Marshall Wace’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-53,100	Closed	-$131K	–	3126
2025 Q1	$131K	Sell	53,100 -518,948	-91%	-$1.23M	﹤0.01%	2467
2024 Q4	$1.8M	Hold	572,048	–	–	﹤0.01%	1490
2024 Q3	$2.82M	Sell	572,048 -31,823	-5%	-$164K	﹤0.01%	1236
2024 Q2	$2.66M	Hold	603,871	–	–	﹤0.01%	1236
2024 Q1	$4.08M	Sell	603,871 -290,311	-32%	-$2.21M	0.01%	1079
2023 Q4	$6.67M	Hold	894,182	–	–	0.01%	811
2023 Q3	$9.09M	Sell	894,182 -267,346	-23%	-$5.68M	0.02%	678
2023 Q2	$24.3M	Buy	+1,161,528	New	+$23.8M	0.05%	413

Other funds holding SLRN

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Marshall Wace's SLRN Position: Q2 2025 in Review

Marshall Wace sold out of ACELYRIN (SLRN) in Q2 2025, closing a stake of 53,100 shares — an estimated $131K sold.

Marshall Wace first reported a position in SLRN in Q2 2023 and held it in 8 quarters. The position peaked at $24.3M in Q2 2023. 2 funds tracked by Wall St. Rank hold SLRN as of Q2 2025.

Marshall Wace reported no remaining ACELYRIN position as of Q2 2025 after selling out during the quarter.
Marshall Wace sold 53,100 ACELYRIN shares in Q2 2025, an estimated $131K.
Marshall Wace first reported a position in ACELYRIN in Q2 2023 and held it in 8 quarters.
Marshall Wace's ACELYRIN position peaked at $24.3M in Q2 2023.
2 funds tracked by Wall St. Rank held ACELYRIN as of Q2 2025.

Based on Marshall Wace's 13F filing for Q2 2025, filed 13 Aug 2025.